TY - JOUR
T1 - Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence-free survival
AU - Subramanian, Sarayu
AU - Han, Gang
AU - Olson, Natalie
AU - Leong, Stanley P.
AU - Kashani-Sabet, Mohammed
AU - White, Richard L.
AU - Zager, Jonathan S.
AU - Sondak, Vernon K.
AU - Messina, Jane L.
AU - Pockaj, Barbara
AU - Kosiorek, Heidi E.
AU - Vetto, John
AU - Fowler, Graham
AU - Schneebaum, Schlomo
AU - Han, Dale
N1 - Publisher Copyright:
© 2021 Wiley Periodicals LLC
PY - 2022/2
Y1 - 2022/2
N2 - Background and Objectives: The prognostic significance of regression in predicting melanoma recurrences is unknown. We present a large multicenter study correlating regression with recurrence. Methods: The Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with regression data. Clinicopathologic factors were correlated with overall and first-site of recurrence and with recurrence-free survival (RFS). Results: There were 4790 patients and the median follow-up was 39.6 months. Regression and recurrences were seen in 1081 (22.6%) and 773 (16.1%) cases, respectively. First-site locoregional and distant recurrences were seen in 412 (8.6%) and 352 (7.3%) patients, respectively. Regression was seen in 15.8% and 24.7% of all cases with and without recurrences (p < 0.0001), respectively, while regression was seen in 14.3% and 17.9% of first-site locoregional and distant recurrent cases, respectively, compared with 23.3% and 22.9% of patients with regression and without first-site locoregional and distant recurrences, respectively (p = 0.29). On multivariable analysis, after controlling for age, gender, thickness, ulceration, lymphovascular invasion, and sentinel lymph node status, regression significantly predicted improved RFS (p = 0.004) and fewer first-site regional recurrences (p = 0.017). Conclusion: Our data suggest that regression is a favorable prognostic marker in melanoma and predicts significantly better RFS and decreased first-site regional recurrences.
AB - Background and Objectives: The prognostic significance of regression in predicting melanoma recurrences is unknown. We present a large multicenter study correlating regression with recurrence. Methods: The Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with regression data. Clinicopathologic factors were correlated with overall and first-site of recurrence and with recurrence-free survival (RFS). Results: There were 4790 patients and the median follow-up was 39.6 months. Regression and recurrences were seen in 1081 (22.6%) and 773 (16.1%) cases, respectively. First-site locoregional and distant recurrences were seen in 412 (8.6%) and 352 (7.3%) patients, respectively. Regression was seen in 15.8% and 24.7% of all cases with and without recurrences (p < 0.0001), respectively, while regression was seen in 14.3% and 17.9% of first-site locoregional and distant recurrent cases, respectively, compared with 23.3% and 22.9% of patients with regression and without first-site locoregional and distant recurrences, respectively (p = 0.29). On multivariable analysis, after controlling for age, gender, thickness, ulceration, lymphovascular invasion, and sentinel lymph node status, regression significantly predicted improved RFS (p = 0.004) and fewer first-site regional recurrences (p = 0.017). Conclusion: Our data suggest that regression is a favorable prognostic marker in melanoma and predicts significantly better RFS and decreased first-site regional recurrences.
UR - http://www.scopus.com/inward/record.url?scp=85115020857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115020857&partnerID=8YFLogxK
U2 - 10.1002/jso.26678
DO - 10.1002/jso.26678
M3 - Article
C2 - 34535899
AN - SCOPUS:85115020857
SN - 0022-4790
VL - 125
SP - 229
EP - 238
JO - Journal of surgical oncology
JF - Journal of surgical oncology
IS - 2
ER -